# Phase 1/2 Myelodysplastic Syndromes trials: 34 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials in phase 1/2 for Myelodysplastic Syndromes that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Myelodysplastic Syndromes trials: 34 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/myelodysplastic-syndromes

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 34
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07888348 | Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT | Ruijin Hospital | Phase 1/2 | Not yet recruiting | Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888348) |
| October 21, 2026 | NCT07885397 | Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1/2 | Recruiting | Myelodysplastic Syndromes, High Risk | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885397) |
| September 1, 2026 | NCT07796620 | Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | Peking University People's Hospital | Phase 1/2 | Not yet recruiting | Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796620) |
| May 15, 2026 | NCT07591168 | A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Myelodysplastic Syndromes | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591168) |
| April 16, 2026 | NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS | Institute of Hematology and Blood Transfusion, Czech Republic | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Proton Therapy, MDS and AML Prior to Allogeneic SCT... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532824) |
| January 28, 2026 | NCT07372885 | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia | University of Manchester | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Cord Blood Stem Cell... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07372885) |
| December 24, 2025 | NCT07301866 | A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe. | Ciusss de L'Est de l'Île de Montréal | Phase 1/2 | Recruiting | Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk, Hematologic Malignancy Requiring an Allogeneic... | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301866) |
| September 4, 2025 | NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar... | AstraZeneca | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155226) |
| April 15, 2025 | NCT06928662 | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment... | Fred Hutchinson Cancer Center | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06928662) |
| April 11, 2025 | NCT06923488 | Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes | West Virginia University | Phase 1/2 | Recruiting | Myelodysplastic Syndromes | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06923488) |
| August 12, 2024 | NCT06548230 | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome... | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548230) |
| March 12, 2024 | NCT06303193 | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Myelodysplastic Syndromes | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06303193) |
| March 7, 2024 | NCT06299462 | PTCy and ATG for MSD and MUD Transplants | Instituto Nacional de Cancer, Brazil | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Non-hodgkin Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06299462) |
| January 16, 2024 | NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | Shenzhen TargetRx Co., Ltd. | Phase 1/2 | Recruiting | Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06206174) |
| January 10, 2024 | NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients | Haukeland University Hospital | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06199557) |
| April 11, 2023 | NCT05807932 | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell... | Heinrich-Heine University, Duesseldorf | Phase 1/2 | Recruiting | Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05807932) |
| February 16, 2023 | NCT05732103 | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Chordia Therapeutics, Inc. | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05732103) |
| November 1, 2022 | NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in... | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05601726) |
| October 18, 2022 | NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | The First Affiliated Hospital with Nanjing Medical University | Phase 1/2 | Recruiting | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05584761) |
| April 11, 2022 | NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Disc Medicine, Inc | Phase 1/2 | Recruiting | Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05320198) |
| April 4, 2022 | NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Rigel Pharmaceuticals | Phase 1/2 | Recruiting | Low Risk Myelodysplastic Syndromes | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05308264) |
| January 6, 2022 | NCT05181735 | Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA | Groupe Francophone des Myelodysplasies | Phase 1/2 | Recruiting | MDS, Myelodysplastic Syndromes | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05181735) |
| December 3, 2021 | NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Cullinan Therapeutics Inc. | Phase 1/2 | Recruiting | Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05143996) |
| October 25, 2021 | NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the... | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05092451) |
| August 18, 2021 | NCT05010122 | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or... | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05010122) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 4 |
| Ellipses Pharma | 1 |
| Ciusss de L'Est de l'Île de Montréal | 1 |
| University Hospital, Basel, Switzerland | 1 |
| Chordia Therapeutics, Inc. | 1 |
| [Rigel Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/rigel-pharmaceuticals) | 1 |
| Haukeland University Hospital | 1 |
| Peking University People's Hospital | 1 |
| Cullinan Therapeutics Inc. | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Groupe Francophone des Myelodysplasies | 1 |
| [Sumitomo Pharma America, Inc.](https://specstream.ai/data/clinical-trials/company/sumitomo-pharma-america-inc) | 1 |
| University of Manchester | 1 |
| PedAL BCU, LLC | 1 |
| West Virginia University | 1 |
| Heinrich-Heine University, Duesseldorf | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |
| Instituto Nacional de Cancer, Brazil | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Institute of Hematology and Blood Transfusion, Czech Republic | 1 |
| Disc Medicine, Inc | 1 |
| Lixte Biotechnology Holdings, Inc. | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Ruijin Hospital | 1 |
| Shenzhen TargetRx Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 18 |
| China | 6 |
| Australia | 5 |
| United Kingdom | 5 |
| France | 4 |
| Canada | 4 |
| Italy | 4 |
| Germany | 3 |
| South Korea | 3 |
| Switzerland | 2 |
| Japan | 2 |
| Spain | 2 |
| New Zealand | 2 |
| Netherlands | 1 |
| Norway | 1 |
| Denmark | 1 |
| Belgium | 1 |
| Singapore | 1 |
| Taiwan | 1 |
| Puerto Rico | 1 |
| Brazil | 1 |
| Czechia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Traffic ticketing law firms in the United States](https://specstream.ai/data/businesses/traffic-ticketing-law-firms/united-states)
- [Diagnostic imaging centers in the United States](https://specstream.ai/data/businesses/diagnostic-imaging-centers/united-states)
- [Nicaraguan restaurants in the United States](https://specstream.ai/data/businesses/nicaraguan-restaurants/united-states)
- [Accounting firms in the United States](https://specstream.ai/data/businesses/accounting-firms/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Polish restaurants in the United States](https://specstream.ai/data/businesses/polish-restaurants/united-states)
